LIV PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
LIV PHARMA
Largest movements
- Cash +€15,211
up €15,211 (+71.8%), from €21,173 to €36,384
mainly Net result for the year (+€18,852) and Accrued charges and deferred income (+€1,426)
- Tangible fixed assets +€909
new in 2025: €909
- Reserves +€18,852
up €18,852 (+136%), from €13,872 to €32,724
- Tax, wage and social debts -€1,767
down €1,767 (-20.8%), from €8,500 to €6,733
of which Taxes: -€1,767
- Accrued charges and deferred income +€1,426
up €1,426 (+106%), from €1,346 to €2,772
- Other debts -€1,013
down €1,013 (-55.6%), from €1,822 to €809
- Trade debts -€879
down €879 (-84.3%), from €1,043 to €164
- Gross operating margin +€7,175
up €7,175 (+35.3%), from €20,319 to €27,494
- Taxes +€2,336
up €2,336 (+39.3%), from €5,944 to €8,280
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €29,583 | €46,202 | +€16,619 | +56.2% |
| Fixed assets | 21/28 | - | €909 | +€909 | |
| Tangible fixed assets | 22/27 | - | €909 | +€909 | |
| Furniture and vehicles | 24 | - | €909 | +€909 | |
| Current assets | 29/58 | €29,583 | €45,293 | +€15,710 | +53.1% |
| Amounts receivable within one year | 40/41 | €8,410 | €8,760 | +€350 | +4.2% |
| Trade receivables | 40 | €8,410 | €8,760 | +€350 | +4.2% |
| Cash at bank and in hand | 54/58 | €21,173 | €36,384 | +€15,211 | +71.8% |
| Deferred charges and accrued income | 490/1 | - | €149 | +€149 | |
| Total equity and liabilities | 10/49 | €29,583 | €46,202 | +€16,619 | +56.2% |
| Equity | 10/15 | €16,872 | €35,724 | +€18,852 | +112% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €13,872 | €32,724 | +€18,852 | +136% |
| Distributable reserves | 133 | €13,872 | €32,724 | +€18,852 | +136% |
| Amounts payable | 17/49 | €12,711 | €10,478 | -€2,233 | -17.6% |
| Amounts payable within one year | 42/48 | €11,365 | €7,706 | -€3,659 | -32.2% |
| Trade debts | 44 | €1,043 | €164 | -€879 | -84.3% |
| Suppliers | 440/4 | €1,043 | €164 | -€879 | -84.3% |
| Taxes, remuneration and social security | 45 | €8,500 | €6,733 | -€1,767 | -20.8% |
| Taxes | 450/3 | €6,500 | €4,733 | -€1,767 | -27.2% |
| Remuneration and social security | 454/9 | €2,000 | €2,000 | = | 0.0% |
| Other amounts payable | 47/48 | €1,822 | €809 | -€1,013 | -55.6% |
| Accrued charges and deferred income | 492/3 | €1,346 | €2,772 | +€1,426 | +106% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €52 | +€52 | |
| Other operating charges | 640/8 | €418 | €316 | -€102 | -24.4% |
| Gross operating margin | 9900 | €20,319 | €27,494 | +€7,175 | +35.3% |
| Operating profit (loss) | 9901 | €19,902 | €27,127 | +€7,225 | +36.3% |
| Financial income | 75/76B | - | €59 | +€59 | |
| Recurring financial income | 75 | - | €59 | +€59 | |
| Financial charges | 65/66B | €86 | €54 | -€32 | -36.8% |
| Recurring financial charges | 65 | €86 | €54 | -€32 | -36.8% |
| Profit (loss) for the period before taxes | 9903 | €19,816 | €27,131 | +€7,315 | +36.9% |
| Income taxes | 67/77 | €5,944 | €8,280 | +€2,336 | +39.3% |
| Profit (loss) for the period | 9904 | €13,872 | €18,852 | +€4,980 | +35.9% |
| Profit (loss) for the period to be appropriated | 9905 | €13,872 | €18,852 | +€4,980 | +35.9% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.